Medical  ||| S:0 E:8 ||| JJ
therapy  ||| S:8 E:16 ||| NN
for  ||| S:16 E:20 ||| IN
ischemic  ||| S:20 E:29 ||| JJ
stroke ||| S:29 E:35 ||| NN
:  ||| S:35 E:37 ||| :
review  ||| S:37 E:44 ||| NN
of  ||| S:44 E:47 ||| IN
intravenous  ||| S:47 E:59 ||| NN
and  ||| S:59 E:63 ||| CC
intra-arterial  ||| S:63 E:78 ||| JJ
treatment  ||| S:78 E:88 ||| NN
options  ||| S:88 E:96 ||| NNS
Thrombolytic  ||| S:96 E:109 ||| JJ
therapy  ||| S:109 E:117 ||| NN
is  ||| S:117 E:120 ||| VBZ
of  ||| S:120 E:123 ||| IN
proven  ||| S:123 E:130 ||| JJ
and  ||| S:130 E:134 ||| CC
substantial  ||| S:134 E:146 ||| JJ
benefit  ||| S:146 E:154 ||| NN
for  ||| S:154 E:158 ||| IN
select  ||| S:158 E:165 ||| JJ
patients  ||| S:165 E:174 ||| NNS
with  ||| S:174 E:179 ||| IN
acute  ||| S:179 E:185 ||| JJ
cerebral  ||| S:185 E:194 ||| JJ
ischemia ||| S:194 E:202 ||| NN
.  ||| S:202 E:204 ||| .
Diagnostic  ||| S:204 E:215 ||| JJ
options  ||| S:215 E:223 ||| NNS
and  ||| S:223 E:227 ||| CC
medical  ||| S:227 E:235 ||| JJ
treatment  ||| S:235 E:245 ||| NN
options  ||| S:245 E:253 ||| NNS
for  ||| S:253 E:257 ||| IN
acute  ||| S:257 E:263 ||| JJ
stroke  ||| S:263 E:270 ||| NN
ischemia  ||| S:270 E:279 ||| NNS
have  ||| S:279 E:284 ||| VBP
undergone  ||| S:284 E:294 ||| VBN
enormous  ||| S:294 E:303 ||| JJ
changes  ||| S:303 E:311 ||| NNS
in  ||| S:311 E:314 ||| IN
the  ||| S:314 E:318 ||| DT
past  ||| S:318 E:323 ||| JJ
decades ||| S:323 E:330 ||| NNS
.  ||| S:330 E:332 ||| .
Whereas  ||| S:332 E:340 ||| IN
initially  ||| S:340 E:350 ||| RB
stroke  ||| S:350 E:357 ||| JJ
treatment  ||| S:357 E:367 ||| NN
was  ||| S:367 E:371 ||| VBD
reduced  ||| S:371 E:379 ||| VBN
to  ||| S:379 E:382 ||| TO
prevention ||| S:382 E:392 ||| NN
,  ||| S:392 E:394 ||| ,
management  ||| S:394 E:405 ||| NN
of  ||| S:405 E:408 ||| IN
symptoms ||| S:408 E:416 ||| NNS
,  ||| S:416 E:418 ||| ,
and  ||| S:418 E:422 ||| CC
rehabilitation ||| S:422 E:436 ||| NN
,  ||| S:436 E:438 ||| ,
nowadays  ||| S:438 E:447 ||| RB
a  ||| S:447 E:449 ||| DT
multitude  ||| S:449 E:459 ||| NN
of  ||| S:459 E:462 ||| IN
different  ||| S:462 E:472 ||| JJ
fibrinolytic  ||| S:472 E:485 ||| JJ
drugs  ||| S:485 E:491 ||| NNS
are  ||| S:491 E:495 ||| VBP
available ||| S:495 E:504 ||| JJ
.  ||| S:504 E:506 ||| .
The  ||| S:506 E:510 ||| DT
wide  ||| S:510 E:515 ||| JJ
availability  ||| S:515 E:528 ||| NN
of  ||| S:528 E:531 ||| IN
computed  ||| S:531 E:540 ||| JJ
tomography  ||| S:540 E:551 ||| NN
in  ||| S:551 E:554 ||| IN
the  ||| S:554 E:558 ||| DT
late  ||| S:558 E:563 ||| JJ
1980s  ||| S:563 E:569 ||| NNS
made  ||| S:569 E:574 ||| VBD
thrombolysis  ||| S:574 E:587 ||| VBN
a  ||| S:587 E:589 ||| DT
real  ||| S:589 E:594 ||| JJ
therapeutic  ||| S:594 E:606 ||| JJ
option  ||| S:606 E:613 ||| NN
because  ||| S:613 E:621 ||| IN
it  ||| S:621 E:624 ||| PRP
allowed  ||| S:624 E:632 ||| VBD
a  ||| S:632 E:634 ||| DT
fast  ||| S:634 E:639 ||| JJ
and  ||| S:639 E:643 ||| CC
accurate  ||| S:643 E:652 ||| JJ
differentiation  ||| S:652 E:668 ||| NN
between  ||| S:668 E:676 ||| IN
ischemic  ||| S:676 E:685 ||| NN
and  ||| S:685 E:689 ||| CC
hemorrhagic  ||| S:689 E:701 ||| JJ
stroke ||| S:701 E:707 ||| NN
.  ||| S:707 E:709 ||| .
This  ||| S:709 E:714 ||| DT
study  ||| S:714 E:720 ||| NN
reviews  ||| S:720 E:728 ||| VBZ
these  ||| S:728 E:734 ||| DT
developments  ||| S:734 E:747 ||| NNS
and  ||| S:747 E:751 ||| CC
how  ||| S:751 E:755 ||| WRB
they  ||| S:755 E:760 ||| PRP
have  ||| S:760 E:765 ||| VBP
shaped  ||| S:765 E:772 ||| VBN
our  ||| S:772 E:776 ||| PRP$
current  ||| S:776 E:784 ||| JJ
use  ||| S:784 E:788 ||| NN
and  ||| S:788 E:792 ||| CC
understanding  ||| S:792 E:806 ||| NN
of  ||| S:806 E:809 ||| IN
thrombolytics  ||| S:809 E:823 ||| NN
in  ||| S:823 E:826 ||| IN
the  ||| S:826 E:830 ||| DT
treatment  ||| S:830 E:840 ||| NN
of  ||| S:840 E:843 ||| IN
acute  ||| S:843 E:849 ||| JJ
ischemic  ||| S:849 E:858 ||| JJ
stroke ||| S:858 E:864 ||| NN
.  ||| S:864 E:866 ||| .
Patient  ||| S:866 E:874 ||| JJ
selection  ||| S:874 E:884 ||| NN
remains  ||| S:884 E:892 ||| VBZ
a  ||| S:892 E:894 ||| DT
central  ||| S:894 E:902 ||| JJ
aspect  ||| S:902 E:909 ||| NN
of  ||| S:909 E:912 ||| IN
thrombolytic  ||| S:912 E:925 ||| JJ
treatment ||| S:925 E:934 ||| NN
,  ||| S:934 E:936 ||| ,
and  ||| S:936 E:940 ||| CC
to  ||| S:940 E:943 ||| TO
date ||| S:943 E:947 ||| NN
,  ||| S:947 E:949 ||| ,
the  ||| S:949 E:953 ||| DT
use  ||| S:953 E:957 ||| NN
of  ||| S:957 E:960 ||| IN
different  ||| S:960 E:970 ||| JJ
fibrinolytics  ||| S:970 E:984 ||| NN
has  ||| S:984 E:988 ||| VBZ
been  ||| S:988 E:993 ||| VBN
studied  ||| S:993 E:1001 ||| VBN
in  ||| S:1001 E:1004 ||| IN
over  ||| S:1004 E:1009 ||| IN
20  ||| S:1009 E:1012 ||| CD
large  ||| S:1012 E:1018 ||| JJ
randomized  ||| S:1018 E:1029 ||| JJ
trials  ||| S:1029 E:1036 ||| NNS
for  ||| S:1036 E:1040 ||| IN
different  ||| S:1040 E:1050 ||| JJ
clinical  ||| S:1050 E:1059 ||| JJ
settings ||| S:1059 E:1067 ||| NNS
,  ||| S:1067 E:1069 ||| ,
time  ||| S:1069 E:1074 ||| NN
windows ||| S:1074 E:1081 ||| NNS
,  ||| S:1081 E:1083 ||| ,
and  ||| S:1083 E:1087 ||| CC
routes  ||| S:1087 E:1094 ||| NNS
of  ||| S:1094 E:1097 ||| IN
administration ||| S:1097 E:1111 ||| NN
.  ||| S:1111 E:1113 ||| .
These  ||| S:1113 E:1119 ||| DT
studies  ||| S:1119 E:1127 ||| NNS
included  ||| S:1127 E:1136 ||| VBD
over  ||| S:1136 E:1141 ||| IN
7000  ||| S:1141 E:1146 ||| CD
patients ||| S:1146 E:1154 ||| NNS
,  ||| S:1154 E:1156 ||| ,
and  ||| S:1156 E:1160 ||| CC
led  ||| S:1160 E:1164 ||| VBN
to  ||| S:1164 E:1167 ||| TO
our  ||| S:1167 E:1171 ||| PRP$
current  ||| S:1171 E:1179 ||| JJ
understanding  ||| S:1179 E:1193 ||| NN
of  ||| S:1193 E:1196 ||| IN
the  ||| S:1196 E:1200 ||| DT
use  ||| S:1200 E:1204 ||| NN
of  ||| S:1204 E:1207 ||| IN
thrombolysis  ||| S:1207 E:1220 ||| NN
in  ||| S:1220 E:1223 ||| IN
acute  ||| S:1223 E:1229 ||| JJ
stroke ||| S:1229 E:1235 ||| NN
.  ||| S:1235 E:1237 ||| .
Intravenous  ||| S:1237 E:1249 ||| JJ
fibrinolytic  ||| S:1249 E:1262 ||| JJ
therapy  ||| S:1262 E:1270 ||| NN
within  ||| S:1270 E:1277 ||| IN
the  ||| S:1277 E:1281 ||| DT
first  ||| S:1281 E:1287 ||| JJ
3  ||| S:1287 E:1289 ||| CD
hours  ||| S:1289 E:1295 ||| NNS
of  ||| S:1295 E:1298 ||| IN
ischemic  ||| S:1298 E:1307 ||| JJ
stroke  ||| S:1307 E:1314 ||| NN
onset  ||| S:1314 E:1320 ||| NN
offers  ||| S:1320 E:1327 ||| VBZ
substantial  ||| S:1327 E:1339 ||| JJ
benefits  ||| S:1339 E:1348 ||| NNS
for  ||| S:1348 E:1352 ||| IN
virtually  ||| S:1352 E:1362 ||| RB
all  ||| S:1362 E:1366 ||| DT
patients  ||| S:1366 E:1375 ||| NNS
with  ||| S:1375 E:1380 ||| IN
potentially  ||| S:1380 E:1392 ||| RB
disabling  ||| S:1392 E:1402 ||| JJ
deficits ||| S:1402 E:1410 ||| NNS
.  ||| S:1410 E:1412 ||| .
In  ||| S:1412 E:1415 ||| IN
the  ||| S:1415 E:1419 ||| DT
3-  ||| S:1419 E:1422 ||| NN
to  ||| S:1422 E:1425 ||| TO
4.5-hour  ||| S:1425 E:1434 ||| CD
treatment  ||| S:1434 E:1444 ||| NN
window ||| S:1444 E:1450 ||| NN
,  ||| S:1450 E:1452 ||| ,
intravenous  ||| S:1452 E:1464 ||| JJ
fibrinolytic  ||| S:1464 E:1477 ||| JJ
therapy  ||| S:1477 E:1485 ||| NN
has  ||| S:1485 E:1489 ||| VBZ
been  ||| S:1489 E:1494 ||| VBN
shown  ||| S:1494 E:1500 ||| VBN
to  ||| S:1500 E:1503 ||| TO
offer  ||| S:1503 E:1509 ||| VB
moderate  ||| S:1509 E:1518 ||| JJ
net  ||| S:1518 E:1522 ||| JJ
benefits  ||| S:1522 E:1531 ||| NNS
when  ||| S:1531 E:1536 ||| WRB
applied  ||| S:1536 E:1544 ||| VBN
to  ||| S:1544 E:1547 ||| TO
all  ||| S:1547 E:1551 ||| DT
patients  ||| S:1551 E:1560 ||| NNS
with  ||| S:1560 E:1565 ||| IN
potentially  ||| S:1565 E:1577 ||| RB
disabling  ||| S:1577 E:1587 ||| JJ
deficits ||| S:1587 E:1595 ||| NNS
.  ||| S:1595 E:1597 ||| .
Intra-arterial  ||| S:1597 E:1612 ||| JJ
fibrinolytic  ||| S:1612 E:1625 ||| JJ
therapy  ||| S:1625 E:1633 ||| NN
in  ||| S:1633 E:1636 ||| IN
the  ||| S:1636 E:1640 ||| DT
3-  ||| S:1640 E:1643 ||| NN
to  ||| S:1643 E:1646 ||| TO
6-hour  ||| S:1646 E:1653 ||| CD
window  ||| S:1653 E:1660 ||| NN
offers  ||| S:1660 E:1667 ||| VBZ
moderate  ||| S:1667 E:1676 ||| JJ
net  ||| S:1676 E:1680 ||| JJ
benefits  ||| S:1680 E:1689 ||| NNS
when  ||| S:1689 E:1694 ||| WRB
applied  ||| S:1694 E:1702 ||| VBN
to  ||| S:1702 E:1705 ||| TO
all  ||| S:1705 E:1709 ||| DT
patients  ||| S:1709 E:1718 ||| NNS
with  ||| S:1718 E:1723 ||| IN
potentially  ||| S:1723 E:1735 ||| RB
disabling  ||| S:1735 E:1745 ||| JJ
deficits  ||| S:1745 E:1754 ||| NNS
and  ||| S:1754 E:1758 ||| CC
large-artery  ||| S:1758 E:1771 ||| JJ
cerebral  ||| S:1771 E:1780 ||| JJ
thrombotic  ||| S:1780 E:1791 ||| JJ
occlusions ||| S:1791 E:1801 ||| NN
.  ||| S:1801 E:1803 ||| .
